Klotho expression in long bones regulates FGF23 production during renal failure

FASEB Journal

Volumn 31, Issue 5, 2017, Pages 2050-2064

  Kaludjerovic, Jovana ^a   Komaba, Hirotaka ^a   Sato, Tadatoshi ^a   Erben, Reinhold G ^b   Baron, Roland ^a,c   Olauson, Hannes ^d   Larsson, Tobias E ^d   Lanske, Beate ^a,c  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bone metabolism; Chronic kidney disease; Fibroblast growth factor 23

Indexed keywords

CALCITRIOL; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; CRE RECOMBINASE; FIBROBLAST GROWTH FACTOR 23; HORSERADISH PEROXIDASE; KLOTHO PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCALCIN; OXYGENASE; PARATHYROID HORMONE; PEPTIDES AND PROTEINS; PRX 1 PROTEIN; UNCLASSIFIED DRUG; BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR; PHOSPHATE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATROPHY; AUTOCRINE EFFECT; BONE DENSITY; BONE TURNOVER; CELL CULTURE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL RENAL FAILURE; FEEDBACK SYSTEM; FEMALE; HISTOLOGY; HYPERPHOSPHATEMIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY ATROPHY; KIDNEY DISEASE; KIDNEY FUNCTION; LONG BONE; MALE; MINERAL METABOLISM; MORPHOMETRY; MOUSE; NEPHRECTOMY; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; UREMIA; ANIMAL; BONE; DEFICIENCY; GENETICS; KIDNEY; KIDNEY FAILURE; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; BONE AND BONES; CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; KIDNEY; MICE, KNOCKOUT; OSTEOBLASTS; PARATHYROID HORMONE; PHOSPHATES; RENAL INSUFFICIENCY;

EID: 85019449771     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.201601036R     Document Type: Article

References (68)

1. De Jager, D. J.,Grootendorst,D. C., Jager, K. J., vanDijk, P. C.,Tomas, L. M., Ansell, D., Collart, F., Finne, P., Heaf, J. G., De Meester, J., Wetzels, J. F., Rosendaal, F. R., and Dekker, F. W. (2009) Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302, 1782-1789
2. Fried, L. F., Biggs, M. L., Shlipak, M. G., Seliger, S., Kestenbaum, B., Stehman-Breen, C., Sarnak, M., Siscovick, D., Harris, T., Cauley, J., Newman,A. B., and Robbins, J. (2007) Association of kidney function with incident hip fracture in older adults. J. Am. Soc. Nephrol. 18, 282-286
3. Pereira,R.C., Juppner,H.,Azucena-Serrano,C. E., Yadin,O., Salusky, I. B., and Wesseling-Perry, K. (2009) Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 45, 1161-1168
4. Wesseling-Perry, K., Pereira, R. C., Wang, H., Elashoff, R.M., Sahney, S., Gales, B., Jüppner, H., and Salusky, I. B. (2009) Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J. Clin. Endocrinol. Metab. 94, 511-517
5. Isakova, T., Xie, H., Barchi-Chung, A., Vargas, G., Sowden, N., Houston, J.,Wahl, P.,Lundquist,A., Epstein,M., Smith,K.,Contreras, G., Ortega, L., Lenz, O., Briones, P., Egbert, P., Ikizler, T. A., Jueppner, H., and Wolf, M. (2011) Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin. J. Am. Soc. Nephrol. 6, 2688-2695
6. Jean, G., Terrat, J.C., Vanel,T.,Hurot, J. M., Lorriaux, C., Mayor, B., and Chazot, C. (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol. Dial. Transplant. 24, 2792-2796
7. Nasrallah, M. M., El-Shehaby, A. R., Salem, M. M., Osman, N. A., ElSheikh, E.,andSharafElDin,U.A. (2010)Fibroblastgrowthfactor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol. Dial. Transplant. 25, 2679-2685
8. Isakova, T., Gutiérrez, O. M., Chang, Y., Shah, A., Tamez, H., Smith, K., Thadhani, R., and Wolf, M. (2009) Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol. 20, 388-396
9. Isakova, T., Xie, H., Yang, W., Xie, D., Anderson, A. H., Scialla, J., Wahl, P., Gutiérrez, O. M., Steigerwalt, S., He, J., Schwartz, S., Lo, J., Ojo, A., Sondheimer, J.,Hsu, C. Y., Lash, J., Leonard,M., Kusek, J. W., Feldman, H. I., and Wolf, M.; Chronic Renal Insufficiency Cohort (CRIC) Study Group. (2011) Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305, 2432-2439
10. Faul, C., Amaral, A. P., Oskouei, B., Hu, M. C., Sloan, A., Isakova, T., Gutiérrez,O.M., Aguillon-Prada, R., Lincoln, J., Hare, J.M.,Mundel, P.,Morales,A., Scialla, J., Fischer,M., Soliman,E. Z.,Chen, J.,Go,A. S., Rosas, S. E., Nessel, L., Townsend, R. R., Feldman, H. I., St John Sutton, M., Ojo, A., Gadegbeku, C., Di Marco, G. S., Reuter, S., Kentrup, D., Tiemann, K., Brand, M., Hill, J. A., Moe, O. W., Kuro-O, M., Kusek, J. W., Keane, M. G., and Wolf, M. (2011) FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393-4408
11. Houston, J., Smith, K., Isakova, T., Sowden, N., Wolf, M., and Gutiérrez, O. M. (2013) Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease. J. Ren. Nutr. 23, 12-20
12. Smith, K., deFilippi, C., Isakova, T., Gutiérrez, O. M., Laliberte, K., Seliger, S., Kelley, W., Duh, S.H., Hise,M., Christenson, R., Wolf,M., and Januzzi, J. (2013) Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD. Am. J. Kidney Dis. 61, 67-73
13. Moe, S. M., Chertow, G. M., Parfrey, P. S., Kubo, Y., Block, G. A., Correa-Rotter, R., Drüeke, T. B., Herzog, C. A., London, G. M., Mahaffey, K. W., Wheeler,D. C., Stolina,M., Dehmel, B., Goodman, W. G., and Floege, J.; Evaluation of CinacalcetHCl Therapy to Lower Cardiovascular Events (EVOLVE)Trial Investigators. (2015) Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Circulation 132, 27-39
14. Fyfe-Johnson, A. L., Alonso, A., Selvin, E., Bower, J. K., Pankow, J. S., Agarwal, S.K., andLutsey, P.L. (2016)Serumfibroblast growth factor-23 and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. J. Hypertens. 34, 1266-1272
15. Wright, C. B., Shah, N. H., Mendez, A. J., DeRosa, J. T., Yoshita, M., Elkind, M. S., Sacco, R. L., DeCarli, C., Rundek, T., Silverberg, S., Dong,C., andWolf,M. (2016)Fibroblast growth factor 23is associated with subclinical cerebrovascular damage: the Northern Manhattan study. Stroke 47, 923-928
16. Olauson, H., Lindberg, K., Amin, R., Sato, T., Jia, T., Goetz, R., Mohammadi,M.,Andersson,G.,Lanske,B., andLarsson,T.E. (2013) Parathyroid-specific deletion of Klotho unravels a novel calcineurindependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet. 9, e1003975
17. Gattineni, J., Bates, C., Twombley, K., Dwarakanath, V., Robinson, M. L., Goetz, R., Mohammadi, M., and Baum, M. (2009) FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly viaFGF receptor 1.Am. J. Physiol. Renal Physiol. 297, F282-F291
18. Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., and Yamashita, T. (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin Dmetabolism. J. Clin. Invest. 113, 561-568
19. Shimada, T., Yamazaki, Y., Takahashi,M., Hasegawa, H., Urakawa, I., Oshima,T.,Ono,K.,Kakitani,M.,Tomizuka,K., Fujita,T., Fukumoto, S., and Yamashita,T. (2005)VitaminDreceptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am. J. Physiol. Renal Physiol. 289, F1088-F1095
20. Andrukhova, O., Zeitz, U., Goetz, R., Mohammadi, M., Lanske, B., andErben,R. G. (2012) FGF23 actsdirectly onrenal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone 51, 621-628
21. Andrukhova, O., Smorodchenko, A., Egerbacher, M., Streicher, C., Zeitz, U., Goetz, R., Shalhoub, V., Mohammadi, M., Pohl, E. E., Lanske, B., and Erben, R. G. (2014) FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J. 33, 229-246
22. Ben-Dov, I. Z., Galitzer, H., Lavi-Moshayoff, V., Goetz, R., Kuro-o,M., Mohammadi,M., Sirkis, R., Naveh-Many, T., and Silver, J. (2007) The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 117, 4003-4008
23. Gutierrez, O., Isakova, T., Rhee, E., Shah, A., Holmes, J., Collerone, G., Jüppner, H., and Wolf, M. (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 16, 2205-2215
24. Van Husen, M., Fischer, A. K., Lehnhardt, A., Klaassen, I.,Möller, K., Müller-Wiefel, D. E., and Kemper, M. J. (2010) Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int. 78, 200-206
25. Christov,M. (2014) Fibroblast growth factor 23 in acute kidney injury. Curr. Opin. Nephrol. Hypertens. 23, 340-345
26. Christov, M., Waikar, S. S., Pereira, R. C., Havasi, A., Leaf, D. E., Goltzman, D., Pajevic, P. D.,Wolf,M., andJüppner,H. (2013) Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int. 84, 776-785
27. Smith, R. C., O'Bryan, L. M., Farrow, E. G., Summers, L. J., Clinkenbeard, E. L., Roberts, J. L., Cass, T. A., Saha, J., Broderick, C., Ma, Y. L., Zeng, Q. Q., Kharitonenkov, A., Wilson, J. M., Guo, Q., Sun, H., Allen, M. R., Burr, D. B., Breyer, M. D., and White, K. E. (2012) Circulating aKlotho influences phosphate handling by controlling FGF23 production. J. Clin. Invest. 122, 4710-4715
28. Olauson, H., Lindberg, K., Amin, R., Jia, T., Wernerson, A., Andersson, G., and Larsson, T. E. (2012) Targeted deletion of Klotho in kidney distal tubule disruptsmineralmetabolism. J. Am. Soc. Nephrol. 23, 1641-1651
29. Raimann, A., Ertl, D. A., Helmreich, M., Sagmeister, S., Egerbacher, M., and Haeusler, G. (2013) Fibroblast growth factor 23 and Klotho are present in the growth plate. Connect. Tissue Res. 54, 108-117
30. Rhee, Y., Bivi, N., Farrow, E., Lezcano, V., Plotkin, L. I., White, K. E., and Bellido, T. (2011) Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 49, 636-643
31. Durland, J. L., Sferlazzo, M., Logan, M., and Burke, A. C. (2008) Visualizing the lateral somitic frontier in the Prx1Cre transgenic mouse. J. Anat. 212, 590-602
32. Martin, J. F., and Olson, E. N. (2000) Identification of a prx1 limb enhancer. Genesis 26, 225-229
33. Logan, M., Martin, J. F., Nagy, A., Lobe, C., Olson, E. N., and Tabin, C. J. (2002) Expression of Cre recombinase in the developingmouse limb bud driven by a Prxl enhancer. Genesis 33, 77-80
34. Jia, T., Olauson, H., Lindberg, K., Amin, R., Edvardsson, K., Lindholm, B., Andersson, G., Wernerson, A., Sabbagh, Y., Schiavi, S., and Larsson, T. E. (2013) A novel model of adenine-induced tubulointerstitial nephropathy in mice. BMC Nephrol. 14, 116
35. Tamagaki, K., Yuan, Q., Ohkawa, H., Imazeki, I.,Moriguchi, Y., Imai, N., Sasaki, S., Takeda, K., and Fukagawa, M. (2006) Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrol. Dial. Transplant. 21, 651-659
36. Ferrari, G. O., Ferreira, J. C., Cavallari, R. T., Neves, K. R., dos Reis, L. M., Dominguez, W. V., Oliveira, E. C., Graciolli, F. G., Passlick-Deetjen, J., Jorgetti, V., and Moysés, R. M. (2014) Mineral bone disorder in chronic kidney disease: head-to-head comparison of the 5/6 nephrectomy and adenine models. BMC Nephrol. 15, 69
37. Zou, H., Zhao, X., Sun, N., Zhang, S., Sato, T., Yu, H., Chen, Q., Weber, H. P., Dard, M., Yuan, Q., and Lanske, B. (2013) Effect of chronic kidney disease on the healing of titanium implants. Bone 56, 410-415
38. Lysaght,A.C., Yuan,Q., Fan, Y.,Kalwani,N., Caruso, P.,Cunnane,M., Lanske, B., and Stanković, K. M. (2014) FGF23 deficiency leads to mixed hearing loss andmiddle earmalformation inmice. PLoSOne 9, e107681
39. Erben, R. G., Mayer, D., Weber, K., Jonsson, K., Jüppner, H., and Lanske,B. (2005)Overexpression ofhumanPHEXunder thehuman beta-actin promoter does not fully rescue theHypmouse phenotype. J. Bone Miner. Res. 20, 1149-1160
40. Dempster, D. W., Compston, J. E., Drezner, M. K., Glorieux, F. H., Kanis, J. A.,Malluche,H.,Meunier, P. J.,Ott, S.M., Recker, R. R., and Parfitt, A. M. (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMRHistomorphometryNomenclatureCommittee. J. BoneMiner. Res. 28, 2-17
41. Biber, J., Stieger, B., Stange, G., and Murer, H. (2007) Isolation of renal proximal tubular brush-border membranes. Nat. Protoc. 2, 1356-1359
42. Walmsley, S. J., Broeckling,C.,Hess,A., Prenni, J., andCurthoys,N. P. (2010) Proteomic analysis of brush-border membrane vesicles isolated frompurified proximal convoluted tubules.Am. J. Physiol. Renal Physiol. 298, F1323-F1331
43. Yuan, Q., Sato, T., Densmore,M., Saito, H., Schüler, C., Erben, R. G., andLanske,B. (2011) FGF-23/Klotho signaling is not essential for the phosphaturic and anabolic functions of PTH. J. Bone Miner. Res. 26, 2026-2035
44. Sitara, D., Kim, S., Razzaque,M. S., Bergwitz, C., Taguchi, T., Schüler, C., Erben, R. G., and Lanske, B. (2008) Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet. 4, e1000154
45. Shalhoub, V., Shatzen, E. M., Ward, S. C., Davis, J., Stevens, J., Bi, V., Renshaw, L., Hawkins, N.,Wang,W., Chen, C., Tsai, M. M., Cattley, R. C., Wronski, T. J.,Xia, X., Li, X., Henley, C., Eschenberg, M., and Richards,W.G. (2012) FGF23neutralizationimproveschronic kidney disease-associated hyperparathyroidismyet increasesmortality. J. Clin. Invest. 122, 2543-2553
46. Suzuki, H., Amizuka, N., Oda, K., Li, M., Yoshie, H., Ohshima, H., Noda, M., andMaeda, T. (2005) Histological evidence of the altered distribution of osteocytes and bone matrix synthesis in Klothodeficient mice. Arch. Histol. Cytol. 68, 371-381
47. Lindberg, K., Amin, R., Moe, O. W., Hu, M. C., Erben, R. G., Östman Wernerson, A., Lanske, B., Olauson, H., and Larsson, T. E. (2014) The kidney is the principal organ mediating klotho effects. J. Am. Soc. Nephrol. 25, 2169-2175
48. Imura, A., Tsuji, Y., Murata, M., Maeda, R., Kubota, K., Iwano, A., Obuse, C., Togashi, K., Tominaga,M., Kita, N., Tomiyama, K., Iijima, J., Nabeshima, Y., Fujioka,M., Asato, R., Tanaka, S., Kojima, K., Ito, J., Nozaki, K.,Hashimoto, N., Ito, T., Nishio, T.,Uchiyama, T., Fujimori, T., and Nabeshima, Y. (2007) alpha-Klotho as a regulator of calcium homeostasis. Science 316, 1615-1618
49. Ohnishi, M., Nakatani, T., Lanske, B., and Razzaque, M. S. (2009) Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int. 75, 1166-1172
50. Pulskens,W. P.,Verkaik,M., Sheedfar, F., van Loon,E. P., van de Sluis, B., Vervloet, M. G., Hoenderop, J. G., Bindels, R. J. and NIGRAM Consortium. (2015) Deregulated renal calcium and phosphate transport during experimental kidney failure. PLoS One 10, e0142510
51. Nikolov, I. G., Joki, N., Nguyen-Khoa, T., Ivanovski, O., Phan, O., Lacour,B., Drüeke,T. B.,Massy,Z.A.,DosReis,L.M., Jorgetti, V.,and Lafage-Proust, M. H. (2010) Chronic kidney disease bone and mineral disorder (CKD-MBD) in apolipoprotein E-deficient mice with chronic renal failure. Bone 47, 156-163
52. Cejka, D., Parada-Rodriguez, D., Pichler, S., Marculescu, R., Kramer, I., Kneissel, M., Gross, T., Reisinger, A., Pahr, D., Monier-Faugere, M. C., Haas,M., and Malluche, H. H. (2016) Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease. Kidney Int. 90, 828-834
53. Lau, W. L., Linnes, M., Chu, E. Y., Foster, B. L., Bartley, B. A., Somerman,M. J.,andGiachelli,C.M. (2013)Highphosphatefeeding promotes mineral and bone abnormalities in mice with chronic kidney disease. Nephrol. Dial. Transplant. 28, 62-69
54. Shigematsu,T.,Kazama, J. J., Yamashita,T., Fukumoto, S.,Hosoya,T., Gejyo, F., and Fukagawa, M. (2004) Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am. J. KidneyDis. 44, 250-256
55. Koh,N., Fujimori, T., Nishiguchi, S., Tamori, A., Shiomi, S.,Nakatani, T., Sugimura, K., Kishimoto, T., Kinoshita, S., Kuroki, T., and Nabeshima, Y. (2001) Severely reduced production of Klotho in human chronic renal failure kidney. Biochem. Biophys. Res. Commun. 280, 1015-1020
56. Komaba, H.,Goto, S., Fujii, H.,Hamada, Y., Kobayashi, A., Shibuya,K., Tominaga, Y.,Otsuki,N., Nibu,K., Nakagawa,K., Tsugawa, N.,Okano, T., Kitazawa, R., Fukagawa, M., and Kita, T. (2010) Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 77, 232-238.
57. Erratum in: Kidney Int. 2010; 77, 834
58. Galitzer, H., Ben-Dov, I. Z., Silver, J., and Naveh-Many, T. (2010) Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 77, 211-218
59. Hu, M. C., Shi, M., Zhang, J., Quiñones, H., Griffith, C., Kuro-o, M., andMoe,O.W. (2011)Klotho deficiency causes vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 22, 124-136
60. Wöhrle, S., Bonny,O., Beluch,N.,Gaulis, S.,Stamm,C., Scheibler,M., Müller,M., Kinzel, B., Thuery, A., Brueggen, J., Hynes,N. E., Sellers, W.R.,Hofmann, F., andGraus-Porta,D. (2011) FGFreceptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signalingandregulating FGF-23 expressionin bone. J. Bone Miner. Res. 26, 2486-2497
61. Xiao, Z., Huang, J., Cao, L., Liang, Y., Han, X., and Quarles, L. D. (2014) Osteocyte-specific deletion of Fgfr1 suppresses FGF23. PLoS One 9, e104154
62. Yu, X., and White, K. E. (2005) Fibroblast growth factor 23 and its receptors. Ther. Apher. Dial. 9, 308-312
63. Quarles, L. D. (2012) Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat. Rev. Endocrinol. 8, 276-286
64. Su, N., Jin, M., and Chen, L. (2014) Role of FGF/FGFR signaling in skeletal development and homeostasis: learning frommousemodels. Bone Res. 2, 14003
65. Lanske, B., and Razzaque, M. S. (2014) Molecular interactions of FGF23 and PTH in phosphate regulation. Kidney Int. 86, 1072-1074
66. Hu, M. C., Kuro-o, M., and Moe, O. W. (2013) Klotho and chronic kidney disease. Contrib. Nephrol. 180, 47-63
67. Yuan, Q., Sitara, D., Sato, T., Densmore, M., Saito, H., Schüler, C., Erben, R. G., and Lanske, B. (2011) PTH ablation ameliorates the anomalies of Fgf23-deficientmice by suppressing the elevated vitamin D and calcium levels. Endocrinology 152, 4053-4061
68. Yuan,Q., Sato, T., Densmore, M., Saito, H., Schüler, C., Erben, R. G., and Lanske, B. (2012)Deletion ofPTHrescues skeletal abnormalities and high osteopontin levels in Klotho2/2 mice. PLoS Genet. 8, e1002726